Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to support the Phase 1b First-In-Human clinical trial of PRP, its lead drug candidate for advanced solid tumors. The collaboration aims to leverage Avance Clinical's expertise and Australia's favorable clinical trial environment to efficiently advance PRP from early trials to later development stages. This trial will assess PRP's safety, tolerability, and preliminary efficacy in patients with advanced cancer, targeting a significant unmet medical need. The partnership highlights a shared commitment to scientific rigor and patient safety in developing innovative cancer treatments.
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
